Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss. This study is seeking participants who have: * at least 50% scalp hair loss due to alopecia areata. * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. * history of clinical response failure to alopecia areata treatment (for children in EU/UK only). All participants in this study will receive either study medicine (ritlecitinib) or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. One-third of participants will receive ritlecitinib higher dose, one-third participants will receive ritlecitinib lower dose, and one-third participants will receive placebo. The study medicine is a capsule that is taken by mouth. It is taken once each day at home. The study will compare the experiences of participants receiving ritlecitinib to participants receiving placebo. This will help see if ritlecitinib is safe and effective. Participants will take part in this study for 6 months. During this time, they will have 8 study visits at the study clinic. The study team will also call participants about 8 times over the phone.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ritlecitinib higher dose
- DRUG Ritlecitinib lower dose
Study Locations (17)
Nebraska
- Ear, Nose and Throat Consultants, LLC — Omaha
- Skin Specialists, PC dba Schlessinger MD — Omaha
- Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist) — Papillion
Texas
- 3A Research - West Location — El Paso
- Austin Institute for Clinical Research — Pflugerville
- Texas Dermatology and Laser Specialists — San Antonio
Florida
- Pediatric Skin Research — Miami
- D&H Tamarac Research Center — Tamarac
Indiana
- Dawes Fretzin Clinical Research Group, LLC — Indianapolis
Oregon
- Northwest Dermatology Institute — Portland
Utah
- AMR Clinical — Layton
Shanghai Municipality
- Huashan Hospital, Fudan University — Shanghai
Miyagi
- Tohoku University Hospital — Sendai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2025-07-31 |
| Est. Completion | 2027-05-18 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029711
The ClinicalTrials.gov registry entry for NCT07029711 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Severe Alopecia Areata appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07029711 reports 17 study locations spanning 12 distinct geographic areas — top geographies include Nebraska, Texas, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07029711 about?
NCT07029711 is a clinical study titled "A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata". The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss. This study is seeking participants who have: * at least 50% scalp hair loss due...
What is the current status of trial NCT07029711?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2025-07-31. Estimated completion is 2027-05-18.
What conditions does trial NCT07029711 study?
This clinical trial studies the following conditions: Severe Alopecia Areata. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07029711?
The interventions under investigation include: Placebo (DRUG), Ritlecitinib higher dose (DRUG), Ritlecitinib lower dose (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07029711?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07029711 being conducted?
This trial has 17 study locations across Florida, Indiana, Nebraska, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.